GCG and Hypoglycemia: With the advent of reliable “closed-loop” insulin administration and adjunct glucose-lowering agents with a low risk of hypoglycaemia, such as glucagon-like peptide-1 (GLP-1)-based therapies [54], the risk of hypoglycaemia may decrease and the benefits of strict control may need to be reassessed, particularly given the signal for improved neurological outcomes with this strategy.